Workflow
达安基因(002030) - 2019 Q1 - 季度财报
DAJYDAJY(SZ:002030)2019-04-29 16:00

Financial Performance - The company's operating revenue for Q1 2019 was ¥252,539,215.94, a decrease of 35.03% compared to ¥388,686,400.95 in the same period last year[8]. - Net profit attributable to shareholders was ¥28,264,522.13, representing a slight increase of 1.67% from ¥27,798,952.61 year-on-year[8]. - Basic earnings per share rose to ¥0.04, up 33.33% from ¥0.03 in the same period last year[8]. - The company's main business revenue decreased by 35.15% to approximately RMB 251.45 million due to the exclusion of YunKang from the consolidated scope[25]. - Operating profit for the current period was ¥36,987,252.94, compared to ¥38,976,308.89 in the previous period, showing a decrease of about 5%[65]. - Net profit for the current period was ¥28,899,197.39, down from ¥31,179,977.82, representing a decline of approximately 7%[65]. - The total comprehensive income for the current period is 28,174,099.20, compared to 30,679,684.14 in the previous period, showing a decrease of approximately 4.89%[72]. Cash Flow - The net cash flow from operating activities improved significantly to ¥9,548,557.09, a 107.49% increase from a negative cash flow of ¥127,533,065.95 in the previous year[8]. - Cash outflows from operating activities totaled $354,853,623.19, down from $926,242,084.15 in the prior period[83]. - The cash flow from operating activities for the current period is 230,203,010.37, down from 374,819,561.85 in the previous period, a decline of about 38.5%[80]. - The company reported a decrease in cash flow from operating activities, with a net cash flow of -$3,765,935.97 compared to $13,044,726.09 previously[89]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,891,606,702.97, reflecting a growth of 6.23% from ¥3,663,327,301.13 at the end of the previous year[8]. - Total liabilities decreased significantly, with long-term borrowings reduced to zero, reflecting a reclassification to current liabilities[25]. - Total current assets amounted to approximately $2.11 billion, with accounts receivable at $687.66 million and inventory at $161.31 million[97]. - Total liabilities reached approximately $1.46 billion, with short-term borrowings at $725.47 million and accounts payable at $109.23 million[103]. - Total equity attributable to shareholders was approximately $1.82 billion, with retained earnings of $222.58 million[105]. Investments and Expenses - The company reported a significant loss of RMB 4.34 million in investment income, reflecting losses from joint ventures[25]. - Research and development expenses were ¥18,209,387.87, a decrease from ¥22,349,220.32, indicating a reduction of about 18%[62]. - The company's financial expenses for the current period are 10,031,685.13, down from 12,052,327.67 in the previous period, indicating a reduction of about 16.8%[73]. - The company experienced a 100% increase in credit impairment losses, amounting to RMB 4.89 million, due to the first-time implementation of new financial standards[25]. Shareholder Information - The total number of shareholders at the end of the reporting period was 88,594, with the top ten shareholders holding a combined 56.23% of the shares[16]. - The company did not report any non-recurring gains or losses that would be classified as regular income during the reporting period[13]. - The company did not engage in any share repurchase transactions during the reporting period[22]. Other Financial Metrics - The weighted average return on net assets was 1.54%, slightly down from 1.60% in the previous year[8]. - The company reported government subsidies recognized in the current period amounting to ¥6,211,751.98[9]. - The company has not reported any new product launches or significant market expansions during this period[70].